Antares Pharma (AMEX:AIS) has lost 0.61% or one cent to settle at $1.64 a share with a volume of 436,000 shares. For the past 52-weeks the stock has been trading between $1.32 and $2.00 a share with an average volume of 544,000 shares. Company trades with a market cap of $137 million and a beta of 0.79.

Antares Pharma, Inc. (Antares) is a pharmaceutical company that focuses on self-injection pharmaceutical products and technologies and gel-based products. The Company's subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares has a multi-product deal with Teva Pharmaceutical Industries, Ltd. (Teva) that includes Tev-Tropin human growth hormone and has partnerships with Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR) that include their human growth hormone (hGH) products.

Ampal American (NASDAQ:AMPL) has gained 10% or $.18 a share to settle at $1.97 with a volume of 42,000 shares traded, compared to its average three-month volume of 19,400 shares. For the past 52 weeks the stock has been trading between $1.39 and $2.94 with an average market cap of $110 million and a beta of 1.04.

Ampal-American Israel Corporation (Ampal) primarily acquires interests in businesses located in the State of Israel or that are Israel-related. The Company's investment focus is principally on companies or ventures where Ampal can exercise significant influence, on its own or with investment partners, and can use its management experience to enhance those investments. It focuses to invest in undervalued assets with an emphasis in sectors, such as: Energy, Chemicals, Telecommunications, Real Estate, Project Development and Leisure Time.

CompuCredit Holdings Corp. (NASDAQ:CCRT) has lost 1.72% or $.11 a share to settle at $6.27 with a volume of 21,000 shares. For the past 52 weeks the stock has been trading between $3.50 and $7.37 with a beta of 2.37.

CompuCredit Holdings Corporation (CompuCredit), formerly CompuCredit Corporation, is a provider of various credit and related financial services and products to or associated with the financially underserved consumer credit market. The Company has contracted with third-party financial institutions pursuant, to which the financial institutions have issued general purpose consumer credit cards, and it has purchased the receivables relating to such accounts on a daily basis. The Company reflects its business lines within five segments: Credit Cards; Investments in Previously Charged-Off Receivables; Retail Micro-Loans; Auto Finance, and Internet Micro-Loans.

SoundBite Communications (NASDAQ:SDBT) has gained 2.59% or seven cents a share to settle at $2.67 with a volume of 2000 shares. for the past 52 weeks the stock has been trading between $2.40 and $3.38 with an average volume of 12,127 shares and a market cap of $44 million.

SoundBite Communications, Inc. is a provider of on-demand, multi-channel proactive customer communications service that enables organizations to design, execute and measure communication campaigns for a variety of marketing, customer care, payment and collection processes. Clients use the Company's Engage platform to communicate with their customers through voice, text and e-mail messages that are relevant, timely, personalized and engaging.

StemCells (NASDAQ:STEM) has gained 3.84% or three cents a share to settle at $.84 a share with a volume of 688,000. For the past 52 weeks the stock has been trading between $.75 a share and $1.27 with an average market cap of $107 million.

StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. The Company is focused on cellular medicine, or the use of stem and progenitor cells as the basis for therapeutics and therapies, and enabling technologies for stem cell research, or the use of cells and related technologies to enable stem cell-based research and drug discovery and development. The primary research and development efforts are focused on cellular medicine, where StemCells seeks to identify and develop stem and progenitor cells as therapeutic agents.

OTCpicks.com is not a registered investment advisers or broker/dealer. OTCpicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: OTCpicks.com has not been compensated for any stocks listed in this stock news report.

Ampal American Israel (NASDAQ:AMPL) has lost 2.5% or five cents a share to settle at $1.95 a share with a light volume of 2900 shares compared to his three-month average volume of 24,124 shares. For the past 52 weeks the stock has been trading between $1.39 and $2.95 with a current market capitalization of $110 million.

Ampal-American Israel Corporation (Ampal) primarily acquires interests in businesses located in the State of Israel or that are Israel-related. The Company's investment focus is principally on companies or ventures where Ampal can exercise significant influence, on its own or with investment partners, and can use its management experience to enhance those investments.

Ballard Power (NASDAQ:BLDP) has gained 6.37% or $.13 a share to settle at $2.17 with an increased volume of 598,000 compared to its average three-month volume of 508,759 shares. For the past 52 weeks the stock has been trading between $1.31 and $3.18 with a current market capitalization of $183 million and a trailing 12 months P/E ratio of fall.

Ballard Power Systems Inc. is engaged in design, development, manufacture, sale and service of fuel cell products for a variety of applications, focusing on motive power (material handling and buses) and stationary power (back-up power, supplemental power, and distributed generation). It is also engaged in proton exchange membrane (PEM) fuel cell development and commercialization.

Santarus Inc. (NASDAQ:SNTS) has lost 7.38% or $.24 a share to settle at $3.01 with an increased volume of 855,023 shares compared to its average three-month volume of 351,600 shares. For the past 52 weeks the stock has been trading between $2.09 and $5.67 with a current market capitalization of 177,000,000 and a P/E ratio of 21.81.

Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by gastroenterologists, endocrinologists and other physicians. As of December 31, 2009, the Company's marketed and approved products included Zegerid Capsules and Powder for Oral Suspension, Glumetza Extended Release Tablets and Immediate-release Omeprazole Tablets.

Quicksilver Resources (NYSE:KWK) has been relatively unchanged losing only 0.26% or four cents a share, settling at $15.63 with a moderate volume of 1.5 million shares compared to its average three-month volume of 1.6 million shares. For the past 52 weeks the stock has been trading between $10.53 and $16.15 with a current market capitalization of $2.66 billion and a P/E ratio of 18.07 for the past 12 months.

Quicksilver Resources Inc. (Quicksilver) is an independent energy company. The Company is primarily engaged in exploration, development and production of unconventional natural gas onshore in North America. Quicksilver owns producing oil and natural gas properties in the United States, principally in Texas, Colorado, Wyoming and Montana, and Canada in Alberta and British Columbia.

BPZ Resources, Inc. (NYSE:BPZ) has gained 1.76% or $.11 a share to settle at $6.36 a share with a price volume of 2,970,000 compared to its average three-month volume of 1.5 million shares. for the past 52 weeks the stock has been trading between $3.03 and $8.24 with a current market capitalization of $735 million.

BPZ Resources, Inc. (BPZ) is an independent oil and gas company focused on the exploration, development and production of oil and natural gas in Peru and Ecuador. The Company has the exclusive rights and license agreements for oil and gas exploration and production covering approximately 2.2 million acres in four blocks in northwest Peru and off the northwest coast of Peru in the Gulf of Guayaquil.

PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: PennyTrader.com has not been compensated for any stocks listed in this stock news report.

EpiCept (NASDAQ: EPCT) has lost almost 12.5% or $.10 to settle at $.76 with an increased volume of 936,841 shares. Company announced that it has entered into a definitive agreement for the purchase of 8.9 million shares of its common stock at point $.80 per share and five-year warrants to purchase up to an estimated 3.6 million shares of stock at an exercise price of $.75 per share. Company will receive approximately $6.6 million in proceeds from the offering.

EpiCept Corporation is a specialty pharmaceutical company focused on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. Its lead product is Ceplene, which when used concomitantly with low-dose interleukin-2 reduced maintenance therapy in the treatment of acute myeloid leukemia (AML). Its cancer portfolio includes crinobulin, a small molecule vascular disruption agent (VDA), and apoptosis inducer for the treatment of patients with solid tumors. It has completed its first Phase I clinical trial for crinobulin.

Ampal American Israel (NASDAQ: AMPL) has gained 2.69% or six cents to settle at $2.22 a share with a light volume of 10,200 shares. Company announced that it expects that EMGs gas supplied to Israel is expected to resume by February 17, 2011.

Ampal-American Israel Corporation primarily acquires interests in businesses located in the State of Israel or that are Israel-related. The Company's investment focus is principally on companies or ventures where Ampal can exercise significant influence, on its own or with investment partners, and can use its management experience to enhance those investments.

Beazer Homes (NYSE: BZH) has gained .73% or four cents to settle at $5.49 a share with the volume of 2,340,949 shares. Company reported a loss of $.66 per share, which is $.20 worse than the Reuters consensus of $.46 a share. revenues also fell 48.2% year-to-year to settle at $110.3 million versus the $164.3 million consensus.

Beazer Homes USA, Inc. (Beazer) is a diversified homebuilder. The Company designs, sells and builds single-family and multi-family homes. The Company acts as the general contractor for the construction of its home communities.

Warner Music Group (NYSE: WMG) has tumbled 10.75% or $.67 with an increased volume of 500,529 shares traded by midday of Tuesday. Investors sold in panic as the company reported a loss of $.12 per share which was seven cents better than the consensus of $.19; and the revenues fell 14.1% year-to-year to $789 million versus the $798 million consensus. Decline in revenue reflected the transition from physical to digital age in the music industry.

Warner Music Group Corp. is a music content company. The Company consists of two businesses: Recorded Music and Music Publishing. The Recorded Music business produces revenue through the marketing, sale and licensing of recorded music in various physical, such as compact discs (CDs), long playings (LPs), and digital versatile discs (DVDs) and digital (such as downloads and ringtones) formats. The Music Publishing business owns and acquires rights to musical compositions, exploits and markets these compositions and receives royalties or fees for their use.

eDiet.com, Inc. (NASDAQ: DIET) has lost almost 3% of its value or one cent with an increased volume of 207,691 shares, which is three times the average volume of 85,551 shares. Today the company's board of directors have approved a rights offering in which stockholders will receive nontransferable rights to purchase additional shares of the company's common stock, which is par value at $0.001 per share

eDiets.com, Inc. uses technology to bring weight loss solutions to both consumers and businesses. The Company generates revenue in four ways. It sells digital weight-loss programs. It also offers a weight loss oriented meal delivery services. The Company derives licensing revenues for the use of the intellectual property and development revenues related to the planning, design and development of private-label nutrition Websites.

PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: PennyTrader.com has not been compensated for any stocks listed in this stock news report.

As the market is making new highs, some analysts predict that the S&P 500 is due for a pullback at 1200 range. Whether this is true or not the market seems to be in an uptrend with Dow Jones rising above 12,100 and NASDAQ reaching 2800. The fact that some companies are even increasing their dividends and the inflow of mergers and acquisitions by midsized companies goes to show that the recovery is starting to pick up speed.

Following are some of the stocks that are making headlines today that are considered microcap, so without further ado let's dive right in. Ampal American (NASDAQ: AMPL) recently announced that it has been advised by the East Mediterranean gas, in which the company has a 12.6% interest, was not damaged by the recent explosion of a gas metering station in Egypt. Because of this the supply gas to EMG, and therefore to EMG's immediate Israeli clients has been interrupted by a fire in a facility not related to EMG. Reuters stated that the gas supply to the EMG should resume operations within a week.

To our surprise the stock has been rallying 5.45% at Monday's open with a 21,085 shares volume which is fairly moderate compared to the three month average volume of 27,223. The stock has been trading in the last 52 weeks between $1.39 up to three dollars even. I would definitely keep an eye out on this stock especially within the next week to see if there is gas supply operations resume within the given time table.

Ampal-American Israel Corporation (Ampal) primarily acquires interests in businesses located in the State of Israel or that are Israel-related. The Company's investment focus is principally on companies or ventures where Ampal can exercise significant influence, on its own or with investment partners, and can use its management experience to enhance those investments. It focuses to invest in undervalued assets with an emphasis in sectors, such as: Energy, Chemicals, Telecommunications, Real Estate, Project Development and Leisure Time.

Our next company is Crystallex (AMEX:KRY) that recently it received a letter from the corporation Venezolana de Guayana then stated that the company's mine operating contract for the loss of Christina's project in Bolivar state Venezuela, has been unilaterally terminated by the CVG. The letter also enclosed a copy of a resolution passed by the CVG on February 3, 2011 which also stated that the MOC is unilaterally terminated.

Investors and traders of course have viewed this news as a pessimistic outcome as the shares of the stock KRY has tumbled 37% at the market open with an astounding volume of 10.6 million shares. The stock has already been in a downtrend for the past seven months as a 52-week range and zigzag around $.13 up to $.77

Crystallex international Corporation normally engages in the development of gold properties in Venezuela. It has principally owned interest in the last Christina's gold project that is located in Sifontes Municipality in Bolivar State Venezuela. the company was founded back in 1984 and is headquartered in Toronto Canada.

EpiCept (NASDAQ: EPCT) has been under a tremendous pressure to keep it stuck price per share above one dollar in the last few months. it today announced positive results coming from the phase 2B trial evaluating the efficacy and safety of the attic NP1chemo that chemo therapy induced peripheral neuropathy. The results of the trial with the intent to treat population demonstrated that the change in average daily new Europe passing intensity scores in the and P1 group has achieved a statistically significant reduction in CPN intensity versus placebo which was the trial's primary endpoint in addition the prespecified subgroup of the ITT population those patients who previously received tax saying chemotherapy also have shown a statistically significant reduction in average daily Europe passing intensity scores this subgroup constitute more than 50% of the ITT population.

Because of this stocks have rallied almost 16% of the market open with a volume of three times the average at 666,000 hundred and 24 shares traded so far. Another $.13 and the company can meet NASDAQ's minimum requirements to sustain its listing on the exchange. For the past two weeks the company has traded between $.33 and $2.45 a share.

EpiCept Corp. normally focuses on the development and commercialization of pharmaceutical products for the treatment of cancer and pain in the United States and Germany one of its main products that has had quite a success is the Ceplene, which was used for the treatment of acute myeloid leukemia.

Another company that is in play today is Inovio Pharmaceuticals (AMEX: INO). the company has gone up 1.55% of the market opens with a volume of 243,887 shares traded by midday. It recently announced that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of LA troll proration without contacting the skin. implementing this new technology can also provide other desirable benefits. By eliminating the insertion of needles used in the conventional electroporation process and reducing the electrical pulsing 2 ns makes this contact contactless device even more tolerable than current electroporation devices.

This companyhas a market capitalization of $135.5 million and has been trading between $.76 and $1.56 in the past 52-week range and has a target of one year estimate of $2.96. The company does not pay dividends at this time.

The company is engaged in the discovery development and delivery of DNA vaccines with a focus on cancers and other infectious diseases. It's the Syncon technology enables the design of DNA-based vaccines are capable of providing cross protection against unmatched strains of pathogens such as influenza.

Almaden Minerals (AMEX: AAU) today announced that to drill explorations and definition programs are now underway at the company's wholly owned Ixtaca gold and silver project located in Puebla state, Mexico. The company's goals for the year 2011 at Almaden is to outline the potential of the Ixtaca zone by a minimum CAD to million drill program. In addition the company states that the drilling in 2011 is designed to explore the size potential of the Ixtaca Zone.

Almaden Minerals Limited, is considered to be an exploration stage company that engages in the acquisition exploration and development of mineral properties in Canada as well as the United States and Mexico. It holds interests in the elk gold and silver property compromising the Siwash gold deposits in Canada and the Caballo Blanco gold in Mexico.

BullsEyeMicrocaps.com is not a registered investment advisers or broker/dealer. BullsEyeMicrocaps.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: BullsEyeMicrocaps.com has not been compensated for any stocks listed in this stock news report.